SPONTANEOUS AND INVITRO ACTIVATION OF SYNOVIAL-FLUID AND PERIPHERAL-BLOOD LYMPHOCYTES IN RHEUMATOID-ARTHRITIS

被引：3

作者：

KONTTINEN, YT

PETTERSSON, T

KEMPPINEN, P

FRIMAN, C

机构：

[1] Division of Rheumatology, Fourth Department of Medicine, Helsinki University Central Hospital, Helsinki, SF-00170

来源：

CLINICAL RHEUMATOLOGY | 1990年 / 9卷 / 03期

关键词：

Gamma-Interferon; Growth Factor Receptors; Lymphocytes; Major Histocompatibility Locus; Rheumatoid Arthritis; Synovial Fluid;

D O I：

10.1007/BF02114392

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Peripheral blood (PB) and synovial fluid (SF) were compared in parallel samples in rheumatoid arthritis (RA). The kinetics of in vitro T-cell activation was assessed in phytohemaglutinin (PHA) stimulated PB or SF mononuclear cell cultures on days 0, 1, 3 and 5. The early lymphocyte activation as assessed by interleukin-2 receptor expression was faster in SF than in PB cell cultures. In particular, IFN-γ secretion was higher in SF than in PB cell cultures (p<0.01). Accordingly, lymphocyte major histocompatibility complex (MHC) locus II antigen expression was higher in SF than in PB cell cultures (53± 7% vs. 21 ± 5%;p<0.01). Our results suggest that lymphocytes, which are particularly effective producers of IFN-γ when stimulated in vitro are sequestered in the diseased joints in RA. © 1990 Springer-Verlag.

引用

页码：325 / 332

页数：8

共 24 条

[1]

Lipsky P., Gold, penicillamine, and antimalarials, Inflammation: Basic Principles and Clinical Correlates, pp. 897-910, (1988)

[2]

Konttinen Y.T., Honkanen V.E.A., Future trends in the treatment of rheumatoid arthritis in the light of current etiopathogenetic theories, Scand J Rheumatol, pp. 7-17, (1988)

[3]

Obert H.J., Hofschneider P.H., Interferon bei chronisher Polyarthritis, Dtsch Med Wochenschr, 110, pp. 1766-1769, (1985)

[4]

Seitz M., Manz G., Frank M., Einsatz von rekombinantem human-Interferon gamma bei Patienten mit rheumatoider Arthritis, Z Rheumatol, 45, pp. 93-99, (1986)

[5]

Lemmel E.M., Franke M., Gaus W., Hartl P.W., Hofschneider P.H., Miehlke K., Machalke K., Obert H.J., Results of a phase II clinical trial on treatment of rheumatoid arthritis with recombinant interferon gamma, Rheumatol Int, 7, pp. 127-132, (1987)

[6]

Cannon G.W., Schindler J., Kennedy S., Emkey R., Denes A., Cohen S., Wolfe F., Saway P., Jaffer A., Weaver A., Cogen L., Long term follow-up of recombinant interferon-gamma in rheumatoid arthritis, Arthritis Rheum, 31, (1988)

[7]

Lemmel E-M., Obert H.J., Hofschneider P.H., Low-dose gamma interferon in treatment of rheumatoid arthritis, Lancet, 1, (1988)

[8]

Veys E.M., Mielants H., Verbruggen G., Grosclaude J-P, Meier W., Galazka A., Schindler J., Interferon gamma in rheumatoid arthritis — a double blind study comparing human recombinant interferon gamma with placebo, J Rheumatol, 15, pp. 570-574, (1988)

[9]

Hasler F., Bluestein H.G., Zvaifler N.J., Epstein L.B., Analysis of the defects responsible for the impaired regulation of EBV-induced B-cell proliferation by rheumatoid arthritis lymphocytes. I. Diminished gamma interferon production in response to autologous stimulation, J Exp Med, 157, pp. 173-188, (1983)

[10]

Lotz M., Tsoukas C.D., Fong S., Dinarello C.A., Carson D.A., Vaughan J.H., Release of lymphokines after infection with Epstein Barr virus in vitro. II. A monocyte dependent inhibitor of interleukin-1 down regulates the production of interleukin-2 and interferongamma in rheumatoid arthritis, J Immunol, 136, pp. 3643-3648, (1986)

← 1 2 3 →